标题
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 8, Issue 10, Pages 587-596
出版商
Springer Nature
发表日期
2011-08-23
DOI
10.1038/nrclinonc.2011.121
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Retinoids, Retinoic Acid Receptors, and Cancer
- (2011) Xiao-Han Tang et al. Annual Review of Pathology-Mechanisms of Disease
- Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
- (2011) H. Shi et al. CANCER RESEARCH
- Trastuzumab resistance: all roads lead to SRC
- (2011) Senthil K Muthuswamy NATURE MEDICINE
- Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
- (2011) P. C. De Witt Hamer NEURO-ONCOLOGY
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proteasome and HDAC: who's zooming who?
- (2010) D. McConkey BLOOD
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- Colorectal cancer in review: the role of the EGFR pathway
- (2010) Muhammad W Saif EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Drug Developers Unveil Strategies Aimed at Imatinib-Resistant CML
- (2010) M. Goozner JNCI-Journal of the National Cancer Institute
- Imatinib treatment of metastatic GIST: don't stop (believing)
- (2010) Michael C Heinrich LANCET ONCOLOGY
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Evolution of biomarker qualification at the health authorities
- (2010) Federico Goodsaid et al. NATURE BIOTECHNOLOGY
- The HER2 testing conundrum
- (2010) Malorye Allison NATURE BIOTECHNOLOGY
- Importance of patient selection for EGFR TKIs in lung cancer
- (2010) Ariel Lopez-Chavez et al. Nature Reviews Clinical Oncology
- Tyrosine-kinase inhibitors—new standard for NSCLC therapy
- (2010) Nagahiro Saijo Nature Reviews Clinical Oncology
- Nilotinib and dasatinib—new 'magic bullets' for CML?
- (2010) Massimo Breccia Nature Reviews Clinical Oncology
- PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations
- (2010) Lisa Hutchinson Nature Reviews Clinical Oncology
- Emerging companion diagnostics for cancer drugs
- (2010) Jocelyn August NATURE REVIEWS DRUG DISCOVERY
- Gene and drug matrix for personalized cancer therapy
- (2010) Tim Harris NATURE REVIEWS DRUG DISCOVERY
- Personalized medicine in oncology: the future is now
- (2010) Richard L. Schilsky NATURE REVIEWS DRUG DISCOVERY
- Cancer Clinical Trials — A Chronic but Curable Crisis
- (2010) Robert C. Young NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
- (2010) James E. Butrynski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic mutations as predictive factors in colorectal cancer
- (2010) A Lièvre et al. ONCOGENE
- Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions
- (2010) V. Shankaran et al. ONCOLOGIST
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
- (2010) O. Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses
- (2010) D. Wodarz PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- HDAC inhibitor-based therapies and haematological malignancy
- (2009) L. Stimson et al. ANNALS OF ONCOLOGY
- Evolving Treatment of Advanced Colon Cancer
- (2009) Neil H. Segal et al. Annual Review of Medicine
- Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients
- (2009) Kathryn A. Phillips et al. CANCER
- Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
- (2009) Susan Fotheringham et al. CANCER CELL
- Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective
- (2009) BM Fine et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
- (2009) David O Azorsa et al. Journal of Translational Medicine
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia
- (2009) Massimo Breccia et al. LEUKEMIA RESEARCH
- FDA holds court on post hoc data linking KRAS status to drug response
- (2009) George S. Mack NATURE BIOTECHNOLOGY
- Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
- (2009) J Mullenders et al. ONCOGENE
- Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer
- (2008) Elizabeth Iorns et al. CANCER CELL
- A Personalized Approach to Cancer Treatment: How Biomarkers Can Help
- (2008) M. J. Duffy et al. CLINICAL CHEMISTRY
- Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients
- (2008) Daniele Santini et al. EJC SUPPLEMENTS
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review of HER2 Breast Cancer Testing
- (2008) Marta Cuadros et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search